With little data available so far from prospective, head-to-head comparisons of therapy sequencing in BRAF-mutated melanoma patients, and conflicting data from previous clinical trials on this issue, it remains unclear which treatment sequence might be best for patients with BRAF-mutant metastatic melanoma. This evidence concerns the gene BRAF and metastatic melanoma.